Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Dabigatran etexilate: a new oral thrombin inhibitor.Circulation. 2011; 123: 1436-1450
- Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009; 361: 1139-1151
- Newly identified events in the RE-LY trial.N Engl J Med. 2010; 363: 1875-1876
- Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011; 365: 883-891
- Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011; 365: 981-992
- Edoxaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2013; 369: 2093-2104
- The need for new oral anticoagulants in clinical practice.J Cardiovasc Med. 2009; 10: 605-609
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.Thromb Haemost. 2010; 103: 1116-1127
- Measuring the anticoagulant effects of target specific oral anticoagulants – reasons, methods and current limitations.J Thromb Thrombolysis. 2013; 36: 187-194
- The new oral anticoagulants and the future of haemostasis laboratory testing.Biochem Med (Zagreb). 2012; 22: 329-341
- The direct thrombin inhibitor hirudin.Thromb Haemost. 2008; 99: 819-829
- The ecarin clotting time, a universal method to quantify direct thrombin inhibitors.Pathophysiol Haemost Thromb. 2003; 33: 173-183
Haemosys Ecarin Chromogenic Assay. ECA-T Kit for quantitative determination of direct synthetic thrombin inhibitors in plasma [package Insert]. JenAffin GmbH, Jena, Germany; 2010.
- Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.Thromb Haemost. 2012; 107: 838-847
- Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.Clin Pharmacokinet. 2008; 47: 47-59
- Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open label, parallel group, single-centre study.Clin Pharmacokinet. 2010; 49: 259-268
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.Br J Clin Pharmacol. 2007; 64: 292-303
- Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.Thromb Haemost. 2013; 110: 543-549
- Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study.Ann Pharmacother. 2012; 46: 1627-1636
- Performance on various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses.Am J Clin Pathol. 2014; 141: 262-267
- Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.Thromb Haemost. 2012; 107: 985-997
- Determination of dabigatran in human plasma samples.Semin Thromb Hemost. 2012; 38: 16-22
- Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.Thromb Haemost. 2011; 105: 371-378
- Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.J Thromb Haemost. 2013; 11: 1495-1502
- The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the hemoclot thrombin inhibitor assay in patient plasma samples.Thromb Haemost. 2013; 110: 308-315
- Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.Blood Coagul Fibrinolysis. 2012; 23: 138-143
- Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.Am J Clin Pathol. 2012; 137: 572-574
- Potential inaccuracy of point-of-care INR in dabigatran-treated patients.Ann Pharmacother. 2011; 45: e40
- Dabigatran falsely elevates point of care international normalized ratio results.Am J Med. 2011; 124: e5-e6
- Interpretation of point-of-care INR in patients treated with dabigatran.Am J Med. 2012; 125: 417-420
- Activated clotting time for control of anticoagulation during surgery.Am Surg. 1985; 51: 274-278
- Blutgerinnungstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren.Klin Wochenschr. 1948; 26: 557-583
- Principles and practice of thromboelastography in clinical coagulation management and transfusion practice.Transfus Med Rev. 2012; 26: 1-13
Available at: http://www.rotem.de. Accessed January 21, 2014.
Available at: http://www.haemonetics.com/en/. Accessed January 21, 2014.
- Coagulation management.Curr Opin Crit Care. 2012; 18: 641-646
- A cell-based model of hemostasis.Thromb Haemost. 2001; 85: 958-965
- Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices.Anesth Analg. 2008; 106: 1366-1375
- Diagnosis of early coagulation abnormalities in trauma patients by rotation thromboelastography.J Thromb Haemost. 2007; 5: 289-295
- Rotation thromboelastometry detects thrombocytopenia and hypofibrinogenaemia during orthotopic liver transplantation.Br J Anaesth. 2010; 104: 422-428
- A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution induced coagulation changes after cardiac surgery.Transfusion. 2012; 52: 14-22
- Comparison of plasma with whole blood prothrombin time and fibrinogen on the same instrument.Am J Clin Pathol. 2010; 133: 550-556
- The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry.Anesth Analg. 2012; 115: 16-21
- Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma.Ann Surg. 2010; 252: 434-442
- Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma.Anesth Analg. 2011; 113: 1003-1012
- The incidence and magnitude of fibrinolytic activation in trauma patients.J Thromb Haemost. 2013; 11: 307-314
- Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy – a porcine model.Br J Anaesth. 2006; 97: 460-467
- Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury.Crit Care. 2010; 14: R62
- Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients.Anesthesiology. 2012; 117: 531-547
- Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy.Transfus Med Hemother. 2012; 39: 104-113
- Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes.J Thromb Haemost. 2012; 10: 1342-1351
- Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial.Anesthesiology. 2013; 118: 40-50
- Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy.Crit Care. 2011; 15: R83
- Use of rotation thromboelastometry (ROTEM) to achieve successful treatment of polytrauma with fibrinogen concentrate and prothrombin complex concentrate.Anaesthesia. 2010; 65: 199-203
- Transfusion of allogeneic blood products in proximal aortic surgery with hyopthermic circulatory arrest: effects of thromboelastometry-guided transfusion management.J Cardiothorac Vasc Anesth. 2013; 27: 1181-1188
- Prothrombin complex concentrate reduces blood loss and enhances thrombin generation in a pig model with blunt liver injury under severe hypothermia.Thromb Haemost. 2011; 106: 724-733
- Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury.Blood. 2011; 118: 1943-1951
- Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion.Cochrane Database Syst Rev. 2011; (CD007871)
- Monitoring patients at risk of massive transfusion with thromboelastography or thromboelastometry: a systematic review.Acta Anaesthesiol Scand. 2011; 55: 1174-1189
- Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests.Clin Chem Lab Med. 2014; 9: 1-10
- The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine.Thromb Haemost. 2012; 108: 586-588
- Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.Blood Coagul Fibrinolysis. 2013; 24: 332-338
- Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets.Blood. 2003; 101: 4844-4846
- An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin time.Acta Anaesthesiol Scand. 2010; 54: 86-89
- Prothrombin complex concentrates and a specific antidote (aDabi-Fab) are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.Crit Care. 2014; 18: R27
- Blood coagulation and the risk of atherothrombosis: a complex relationship.Thromb J. 2004; 2: 12
- The impact of blood coagulability on atherosclerosis and cardiovascular disease.J Thromb Haemost. 2012; 10: 1207-1216
- Thrombin generation, a function test of the haemostatic-thrombotic system.Thromb Haemost. 2006; 96: 553-561
- The mode of action of heparin in plasma.Thromb Haemost. 1988; 60: 457-462
- Recollections on thrombin generation.J Thromb Haemost. 2008; 6: 219-226
- The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability.Pathophysiol Haemost Thromb. 2002; 32: 249-253
- Thrombin generation in plasma: its assessment via the endogenous thrombin potential.Thromb Haemost. 1995; 74: 134-138
- Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method.J Thromb Haemost. 2012; 10: 2544-2554
- Assessment of thrombin generation II: validation of the calibrated automated thrombogram in platelet-poor plasma in a clinical laboratory.Thromb Haemost. 2008; 100: 362-364
- Thrombin generation tests.Thromb Res. 2011; 127: S21-S25
- Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study.J Thromb Haemost. 2009; 7: 1639-1648
- The endogenous thrombin potential and the risk of venous thromboembolism.Thromb Res. 2007; 121: 353-359
- Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation.JAMA. 2006; 296: 397-402
- High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism.J Thromb Haemost. 2008; 6: 1327-1333
- High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study.J Thromb Haemost. 2008; 6: 1720-1725
- Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence.Br J Haematol. 2007; 138: 769-774
- Thrombin generation in patients after acute deep-vein thrombosis.Thromb Haemost. 2008; 100: 240-245
- Thrombin generation in clinical conditions.Thromb Res. 2012; 129: 367-370
- Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease.Stroke. 2004; 35: 1085-1089
- Increased thrombin generation in persons with echogenic carotid plaques.Thromb Haemost. 2008; 99: 602-608
- Accelerated in vivo thrombin formation independently predicts the presence and severity of CT angiographic coronary atherosclerosis.JACC Cardiovasc Imaging. 2012; 5: 1201-1210
- Thrombin generation in patients with a first acute myocardial infarction.J Thromb Haemost. 2011; 9: 450-456
- Thrombin generation in the Glasgow Myocardial Infarction Study.PLoS One. 2013; 8: e66977
- Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test.Thromb Haemost. 2008; 99: 382-387
- Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study.J Thromb Haemost. 2011; 9: 2243-2250
- Tests of global haemostasis and their applications in bleeding disorders.Haemophilia. 2010; 16: 85-92
- Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.Blood. 2010; 116: 5734-5737
- Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.Hosp Pract (1995). 2013; 41: 19-25
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor.Thromb Haemost. 2010; 103: 815-825
- In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.J Thromb Haemost. 2007; 5: 886-888
- Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma.Blood Coagul Fibrinolysis. 2011; 22: 588-592
- In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.Thromb Haemost. 2007; 98: 155-162
- Effects of dabigatran in vitro on thrombin biomarkers by calibrated automated thrombography in patients after ischemic stroke.J Thromb Thrombolysis. 2012; 33: 22-27
- Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.Thromb Haemost. 2011; 106: 1076-1083
- The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin.J Thromb Haemost. 2010; 8: 1281-1289
- Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.Eur J Pharmacol. 2005; 514: 35-42
- Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro.Thromb Res. 2001; 104: 475-486
Article info
Publication history
Published online: July 21, 2014
Footnotes
Conflicts of Interest: J. van Ryn is an employee of Boehringer Ingelheim. O. Grottke has received research funding from Boehringer Ingelheim, Biotest, CSL Behring, Novo Nordisk, and Nycomed and honoraria for consultancy and/or travel support from Bayer Healthcare, Boehringer Ingelheim, and CSL Behring. H. Spronk has received research funding from Boehringer Ingelheim and honoraria for consultancy and/or travel support from Bayer Healthcare and Boehringer Ingelheim.
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
